One thing that hasn’t changed since 2017 is the strong defense of Medicaid from Democrats, hospital executives, and consumer ...

The FDA has approved Welireg (belzutifan) for the treatment of patients aged 12 years and older with locally advanced, unresectable, or metastatic pheochromocytoma or paraganglioma.

The risk of recurrence was generally low among cervical cancer patients with no high-risk factors who underwent radical surgery without adjuvant therapy.

The FDA has granted accelerated approval to Avmapki (avutometinib) plus Fakzynja (defactinib) for the treatment of KRAS-mutated, recurrent low-grade serous ovarian cancer.

The Trump administration has terminated National Institutes of Health (NIH) grants totaling more than $1.8 billion, and the National Cancer Institute (NCI) is among the top 5 institutes with the most ...

The HHS and FDA are encouraging stakeholders to submit their ideas for deregulatory actions in the next 60 days.

Researchers found a significant tradeoff between harms and benefits for patients who received an ICI plus chemotherapy in the first-line setting.

Penpulimab-kcqx, a humanized immunoglobulin G1 monoclonal antibody, blocks the interaction between the programmed death 1 receptor on T-cells and programmed death ligand 1 and 2 on tumor cells.

Zongertinib conferred a clinically meaningful benefit in patients with previously treated, advanced, HER2-mutant NSCLC in a phase 1 trial.

Our trial provides proof of concept that cytokine-armored CAR T-cell treatment is feasible and may enhance antitumor activity without additional toxic effects,” researchers reported.

B-cell maturation antigen (BCMA)-directed bispecific antibodies have tolerable safety profiles in frail patients with relapsed/refractory multiple myeloma (MM), according to a real-world study ...

The researchers also observed significant increases in mortality for at least 1 age group for the following cancers: testicular cancer, uterine cancer, female breast cancer, bone and joint cancer, ...